LOGIN  |  REGISTER
Amneal Pharmaceuticals
Cue Biopharma

R1 RCM to Present at Upcoming Investor Conferences

February 16, 2024 | Last Trade: US$14.31 0.00 0.00

MURRAY, Utah, Feb. 16, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming conferences:

  • The 2024 TD Cowen Healthcare Conference on Monday, March 4 at 10:30am ET
  • The 2024 Barclays Global Healthcare Conference on Wednesday, March 13 at 4:35pm ET

A live audio webcast of each presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contacts

Investor Relations:
Evan Smith, CFA
(516) 743-5184
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact: 
Yancey Casey
Amendola Communications
(678) 895-9401
This email address is being protected from spambots. You need JavaScript enabled to view it.


Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page